Choice of therapy for aerobic vaginitis: a clinical and microbiological comparison
Open Access
- 30 September 2025
- journal article
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 27-32
Abstract
Aerobic vaginitis (AV) is an inflammatory disease of the vagina that occurs as a result of dysbiosis of the vaginal environment with a predominance of aerobic opportunistic microorganisms, such as Escherichia coli, Staphylococcus aureus, Streptococcus spp., etc. Frequent recurrence and insufficient diagnosis determine the relevance of research into effective methods of therapy for this disease.The objective: to compare the clinical and microbiological efficacy of two vaginal combination preparations in the treatment of AV in non-pregnant women.Materials and methods. The study included 80 non-pregnant women aged 18 to 45 years with a confirmed diagnosis of AV. The patients were randomized into two equal groups: the main group received medication Tergynan (ternidazole, neomycin sulfate, nystatin, prednisolone sodium metasulfobenzoate), and the comparison group received another combination preparation (ornidazole, miconazole, neomycin sulfate, prednisolone). Diagnostics included microscopy, bacteriological examination of vaginal discharge, gynecological examination, and a patient questionnaire. Treatment effectiveness was evaluated on the 11th and 30th days after therapy.Results. Patients in the main group experienced faster clinical symptom relief (1–2 days earlier) and the frequency of complete recovery immediately after the end of therapy was 85% versus 62% in the comparison group. After 30 days, recurrence occurred in only 9% of women who used Tergynan versus 36% in the comparison group.Conclusions. Tergynan demonstrated significantly higher clinical and microbiological efficacy in the treatment of AV, which justifies its advantages as the drug of choice in the case of this pathology.Keywords
This publication has 21 references indexed in Scilit:
- Aerobic vaginitis, bacterial vaginosis, and vaginal candidiasis among women of reproductive age in Arba Minch, southern EthiopiaScientific Reports, 2024
- Aerobic vaginitis in the third trimester and its impact on pregnancy outcomesBMC Pregnancy and Childbirth, 2022
- Efficacity of ternidazole-neomycin sulfate-nystatin and prednisolone association in syndromic management of vaginitis in low and middle incomes countriesInternational Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2022
- The pathogenesis of prevalent aerobic bacteria in aerobic vaginitis and adverse pregnancy outcomes: a narrative reviewReproductive Health, 2022
- A modern view on cervicovaginal dysbiosis caused by bacterial vaginosis asocated bacteria and yeast-like fungi of the genus Candida (Literature review and own data)HEALTH OF WOMAN, 2020
- 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal dischargeInternational Journal of STD & AIDS, 2018
- Aerobic vaginitis: no longer a strangerResearch in Microbiology, 2017
- Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a reviewArchives of Gynecology and Obstetrics, 2015
- Aerobic vaginitis in pregnancyBJOG: An International Journal of Obstetrics & Gynaecology, 2011
- A Double-blind Treatment Study of Bacterial Vaginosis with Normal Vaginal Lactobacilli after an Open Treatment with Vaginal Clindamycin OvulesActa Dermato-Venereologica, 2005